Effects of prostaglandin F2α on adipocyte biology relevant to graves' orbitopathy

Thyroid

Volumn 23, Issue 12, 2013, Pages 1600-1608

  Draman, Mohd Shazli ^a   Grennan Jones, Fiona ^a   Zhang, Lei ^a   Taylor, Peter N ^a   Tun, Tommy Kyaw ^b   McDermott, John ^b   Moriarty, Paul ^c   Morris, Daniel ^d   Lane, Carol ^d   Sreenan, Seamus ^b   Dayan, Colin ^a   Ludgate, Marian ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Royal College of Surgeons in Ireland   (Ireland)

^c ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; LIPOPROTEIN LIPASE; NORADRENALIN; PROSTAGLANDIN F2 ALPHA; STEROID;

ADIPOGENESIS; ADULT; ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN 3T3; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOLOGY; DECOMPRESSION SURGERY; DRUG EFFECT; ENDOCRINE OPHTHALMOPATHY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPOLYSIS; M PHASE CELL CYCLE CHECKPOINT; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROADIPOCYTE; THYROID DISEASE;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELL PROLIFERATION; DINOPROST; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; LIPOLYSIS; MICE;

EID: 84890362600     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0194     Document Type: Article

References (36)

1. Eisenberg DL, Toris CB, Camras CB 2002 Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 47 Suppl 1:S105-S115. (Pubitemid 35238026)
2. Peplinski LS, Albiani Smith K 2004 Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 81: 574-577. (Pubitemid 39095648)
3. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL 2008 Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 24: 302-307.
4. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D 2008 [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - can bimatoprost cause enophthalmos?]. Klin Monbl Augenheilkd 225: 443-445. (Pubitemid 352016479)
5. Yam JC, Yuen NS, Chan CW 2009 Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 25: 471-472.
6. Aydin S, Isikligil I, Teksen YA, Kir E 2010 Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutan Ocul Toxicol 29: 212-216.
7. Park J, Cho HK, Moon JI 2011 Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 55: 22-27.
8. Jayaprakasam A, Ghazi-Nouri S 2010 Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit 29: 357-359.
9. Serrero G, Lepak NM 1997 Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun 233: 200-202. (Pubitemid 27215935)
10. Balapure AK, Rexroad CE Jr, Kawada K, Watt DS, Fitz TA 1989 Structural requirements for prostaglandin analog interaction with the ovine corpus luteum prostaglandin F2 alpha receptor. Implications for development of a photoaffinity probe. Biochem Pharmacol 38: 2375-2381. (Pubitemid 19173880)
11. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R 1994 Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269: 2632-2636. (Pubitemid 24235760)
12. Sugimoto Y, Hasumoto K, Namba T, Irie A, Katsuyama M, Negishi M, Kakizuka A, Narumiya S, Ichikawa A 1994 Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem 269: 1356-1360. (Pubitemid 24032530)
13. Black FM, Wakelam MJ 1990 Activation of inositol phospholipid breakdown by prostaglandin F2 alpha without any stimulation of proliferation in quiescent NIH-3T3 fibroblasts. Biochem J 266: 661-667. (Pubitemid 20103695)
14. Nakao A, Watanabe T, Taniguchi S, Nakamura M, Honda Z, Shimizu T, Kurokawa K 1993 Characterization of prostaglandin F2 alpha receptor of mouse 3T3 fibroblasts and its functional expression in Xenopus laevis oocytes. J Cell Physiol 155: 257-264. (Pubitemid 23134863)
15. Liu L, Clipstone NA 2007 Prostaglandin F2alpha inhibits adipocyte differentiation via a G alpha q-calcium-calcineurin- dependent signaling pathway. J Cell Biochem 100: 161-173. (Pubitemid 44958187)
16. Neal JW, Clipstone NA 2002 Calcineurin mediates the calcium- dependent inhibition of adipocyte differentiation in 3T3-L1 cells. J Biol Chem 277: 49776-49781. (Pubitemid 36014424)
17. Krassas GE, Heufelder AE 2001 Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144: 311-318. (Pubitemid 32409582)
18. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21: 168-199. (Pubitemid 32275594)
19. Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R, Ludgate M 2009 Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem 284: 26447-26455.
20. Bartley GB 1994 The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92: 477-588.
21. Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM, Earnest Ft 1986 Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. Am J Neuroradiol 7: 651-656. (Pubitemid 16099150)
22. Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M 2006 Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci 47: 5197-5203. (Pubitemid 46723765)
23. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M 2003 Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30: 369-380. (Pubitemid 36722625)
24. Crisp M, Starkey KJ, Lane C, Ham J, Ludgate M 2000 Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 41: 3249-3255.
25. Casimir DA, Miller CW, Ntambi JM 1996 Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation 60: 203-210. (Pubitemid 26265757)
26. Lalic H, Lukinovic-Skudar V, Banfic H, Visnjic D 2012 Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells. Leuk Lymphoma 53: 2253-2261.
27. Meyer zu Horste M, Stroher E, Berchner-Pfannschmidt U, Schmitz-Spanke S, Pink M, Gothert JR, Fischer JW, Gulbins E, Eckstein AK 2011A novel mechanism involved in the pathogenesis of Graves ophthalmopathy (GO): clathrin is a possible targeting molecule for inhibiting local immune response in the orbit. J Clin Endocrinol Metab 96:E1727- E1736.
28. Kumar S, Coenen MJ, Scherer PE, Bahn RS 2004 Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 89: 930-935. (Pubitemid 38269913)
29. Seibold LK, Ammar DA, Kahook MY 2013 Acute effects of glaucoma medications and benzalkonium chloride on preadipocyte proliferation and adipocyte cytotoxicity in vitro. Curr Eye Res 38: 70-74.
30. Choi HY, Lee JE, Lee JW, Park HJ, Jung JH 2012 In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes. J Ocul Pharmacol Ther 28: 146-152.
31. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M 2003 Peroxisome proliferator-activated receptor- gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 88: 55-59. (Pubitemid 36115143)
32. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A 2002 Orbital fibroblast heterogeneity may determine the clinical presentation of thyroidassociated ophthalmopathy. J Clin Endocrinol Metab 87: 385-392. (Pubitemid 34084719)
33. Maxey KM, Johnson JL, LaBrecque J 2002 The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 47 Suppl 1:S34-S40. (Pubitemid 35232217)
34. Hellberg MR, Ke T-L, Haggard K, Klimko PG, Dean TR, Graff G 2003 The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J Ocul Pharmacol Ther 19: 97-103. (Pubitemid 36539135)
35. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ 2001 The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 45 Suppl 4:S337-S345.
36. Ichhpujani P, Katz LJ, Hollo G, Shields CL, Shields JA, Marr B, Eagle R, Alvim H, Wizov SS, Acheampong A, Chen J, Wheeler LA 2012 Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther 28: 134-145.